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Introduction
Helicobacter pylori is one of the most common world-
wide infections, affecting approximately half of the
world’s population.1 These bacteria play a causative
role in the development of gastritis, peptic ulcers, gastric
B cell lymphoma, and gastric cancer,2 and their eradi-
cation reduces the recurrence of peptic ulcer disease
cost-effectively.3 H. pylori was also classified as a class I
carcinogen by the World Health Organization in 1994.
The test-and-treat strategy for H. pylori infection is
a proven management strategy for patients with unin-
vestigated dyspepsia who are under the age of 55 years
and have no “alarm features”.4 Deciding which test to
use in a particular situation depends heavily on whether
a patient requires evaluation with upper endoscopy and
an understanding of the strengths, weaknesses, and costs
of individual tests.4 Noninvasive test-and-treat strategies
are widely recommended in the primary care setting.5
A simple, rapid, accurate, and cost-effective diagnostic
method is essential for H. pylori detection.
Serology is a widely available, discriminating (high
negative predictive value), and cost-effective noninva-
sive test.4 It requires no specialized equipment or
technique and can be performed in most hospitals or
clinic laboratories.5 Enzyme-linked immunosorbent
assay (ELISA) has been the most commonly used
serologic test because it is suitable for screening large
populations.6,7
There are several studies showing lower sensitivity
and higher specificity in younger age groups (< 45
years) compared with older groups (≥ 45 years) in the
serologic diagnosis of H. pylori infection.8–10 It has
been reported that the specificity of the immunoglob-
ulin G (IgG) antibody test for H. pylori declines in
older age groups because of increased atrophic gastritis
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at older ages.11 It has also been demonstrated that the
performance of diagnostic assays may vary between dif-
ferent races and geographic regions, possibly due to the
different antigenic properties of local bacterial strains
and antibodies of commercial kits used for H. pylori
detection.12–14 Therefore, serologic assays for H. pylori
should be evaluated in a local setting.
This study aimed to investigate the effects of in-
creasing age and atrophic gastritis on the diagnostic
accuracy of the Helicobacter IgG antibody test in adults.
To the best of our knowledge, this is the first study on
IgG antibodies against H. pylori in patients with
atrophic gastritis in Taiwan.
Methods
Patient population
Dyspeptic patients scheduled for upper gastrointestinal
endoscopy were recruited from July 1998 to August
1999. Patients with any of the following conditions
were excluded: (1) ulcer complications such as bleed-
ing, stenosis, or perforation; (2) previous gastric sur-
gery; (3) intake of any substituted benzimidazoles or
preparations containing bismuth within 1 month prior
to the test; and (4) previous or current treatment with
anti-H. pylori therapy.
H. pylori status
During endoscopy, 3 sets of gastric biopsy specimens
from the greater curvature of the mid-body and the
antral lesser curvature near the incisura were obtained
for urease testing (CLO test; Delta West Ltd., Bentley,
Australia), histology, and culture. The CLO test was
considered positive for H. pylori if there was a color
change from orange to pink within 24 hours.15 For
histology, H. pylori was considered present when curved
rods were identified in hematoxylin and eosin, or mod-
ified Giemsa staining. In culture, the biopsy sample was
homogenized with 0.3 mL of broth, plated on choco-
late agar, and incubated at 37°C in a micro-aerobic
(15% CO2 and 5% O2) incubator until the colony ap-
peared, which was usually after 3 days. Negative plates
were kept for 7 days. The growth of H. pylori was
confirmed by the characteristic morphology (Gram-
negative and curved) and if positive catalase, oxidase
and urease reactions were observed.
A patient was classified as H. pylori-positive if the
culture or both CLO and histologic tests were positive.
A patient was classified as H. pylori-negative if all 3
methods (culture, CLO, and histology) were negative.
Patients with only 1 positive test on CLO or histology
were considered “indeterminate”.
Serology
For serology studies, blood was drawn immediately
after endoscopy and sera were collected and stored at
–70°C until assay. Fasting serum pepsinogen-I was
measured in all patients by radioimmunoassay (Pepsik;
Sorin Biomedica, Saluggia, Italy) according to the
manufacturer’s instructions. Basal pepsinogen-II levels
were determined using a specific enzyme immunoassay
(BIOHIT Oyj, Helsinki, Finland).
Quantitative ELISA test
Serum specimens were tested for the presence of IgG
antibodies against H. pylori using a quantitative ELISA
test (HEL-pTEST II; AMRAD, Kew, Australia) ac-
cording to the manufacturer’s instructions.16 Reference
standards were used to produce a standard curve to
quantify H. pylori antibody levels in patient samples.
Results were expressed in arbitrary units per mL. A spec-
imen was considered positive if it contained > 50 units/
mL and negative if it contained < 30 units/mL. Sam-
ples with a reading between 30 and 50 units/mL
were classified as undetermined.
Statistical analysis
Statistical analyses were performed using the χ2 test.
Sensitivity, specificity, positive predictive value (PPV)
and negative predictive value (NPV) were determined
for ELISA and compared with the “gold standard”,
which is positive culture or both urease and histology
test positive. Statistical analyses were performed using
SPSS version 15.0 (SPSS Inc., Chicago, IL, USA). A 
p value < 0.05 was considered statistically significant.
Results
One hundred and seventy patients (88 males and 82
females; mean age, 44 years; age range, 20–70 years)
were included in the study. The H. pylori prevalence
rate was 54.9% (50/91) in patients aged < 45 years and
69.6% (55/79) in those ≥45 years (p=0.058). Twenty-
one patients were ELISA indeterminate, and 1 was 
H. pylori indeterminate.
In patients < 45 years old, 8 were excluded because
of an indeterminate ELISA test. Of the 79 patients ≥
45 years, 13 were ELISA indeterminate. The specificity
was lower in those aged ≥ 45 years, but this was not
statistically significant (Table 1).
Twenty-six patients were diagnosed with atrophic
gastritis by the criteria (serum pepsinogen-I ≤ 70 μg/L
and a pepsinogen-I/pepsinogen-II ratio ≤ 3).11 One
hundred and twenty-two patients were diagnosed with
non-atrophic gastritis by these criteria (Table 2). ELISA
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showed a high sensitivity (96.5%) and specificity (91.9%)
in the non-atrophic gastritis group. Specificity (86.7%)
and PPV (84.6%) were lower in the atrophic gastritis
group, but sensitivity and NPV were 100%.
Discussion
The prevalence of H. pylori has epidemic variations,
infecting more than 80% of adults in Japan and 40%
in the UK.17 The prevalence of infection increases with
age, although this may be largely a cohort effect.1 The
choice of an initial test for detecting H. pylori depends
on the prevalence of H. pylori infection and the diag-
nostic accuracy.5
A single test, except for culture, is not sufficient
for diagnosis.5 Therefore, the European Guidelines
indicate that the gold standard should be generally
represented by at least 2 different tests.5,18 In this study,
a patient was diagnosed as having H. pylori infection
when the culture or both CLO and histology were
positive. A serology test has the lowest cost per correct
diagnosis, but its diagnostic accuracy is low (80–84%).5
However, some serology kits with a high accuracy
(> 90%) have been reported in validated settings.18,19
The sensitivity and specificity of ELISA depends on
the antigen used, the clinical context, the gold standard
used for comparison, and the prevalence of H. pylori
in the community.5 Although setting a gray zone for
ELISA will decrease its effectiveness as a screening
tool, it is still a very useful and suitable tool for epidemi-
ological studies. Studies in the UK have also demon-
strated that serology is the method of choice in screening
before direct access upper gastrointestinal endoscopy
in those < 45 years old because it shows a high sensi-
tivity for peptic ulcer disease with a large reduction in
unnecessary negative endoscopies.15,20
The sensitivity of ELISA-based testing ranges be-
tween 90% and 97%, while specificity is between 50%
and 96%.5,21–23 Serology has a similarly high sensitivity
in different age groups but declining specificity in older
groups.11 In the current study, the quantitative ELISA
test with IgG antibodies against H. pylori disclosed a
high sensitivity in different age groups but lower speci-
ficity (86.7%) in the older age group, which is consis-
tent with previous studies.11
Atrophic gastritis is an important risk factor for
gastric cancer. Approximately one-third of H. pylori-
infected patients have atrophic gastritis in Finland.24
H. pylori infection is associated with 84% of atrophic
corpus gastritis.24 Although histology is currently the
standard method for the detection of atrophy, it is not
a “gold standard” because of interobserver variability,
especially in mild atrophy gastritis and potential sam-
pling error in patients with patchy distribution of the
mucosal alterations.25 The current study concluded that
a pepsinogen-I/pepsinogen-II ratio ≤ 3 was a reliable
marker for the diagnosis of atrophic gastritis.25 In the
present study, we recruited patients aged between 20
and 70 years (mean age, 44 years). Twenty-six of the
170 patients had atrophic gastritis by the serum
pepsinogen criteria. The prevalence of atrophic gastritis
was low (26/170, 15.3%), which may be due to a rela-
tively younger age, geographic differences, and differ-
ence in race.
Serologic tests are recommended for assessing 
H. pylori in patients with a low bacterial density [exten-
sive mucosal atrophy and MALT (mucosa-associated
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Table 1. Effect of age on the diagnostic value of ELISA in detecting H. pylori infection
Age
True False True False Sensitivity Specificity PPV NPV Accuracy 
positive positive negative negative (%) (%) (%) (%) (%)
< 45 yr (n = 90) 43 2 34 3 93.5 94.4 95.6 91.9 93.9
≥ 45 yr (n = 79) 50 3 13 0 100 81.3 94.3 100 95.6
PPV = positive predictive value; NPV = negative predictive value; ELISA = HEL-pTEST II (quantitative ELISA test).
Table 2. Effect of atrophic gastritis on the diagnostic value of ELISA in detecting H. pylori infection
Age
True False True False Sensitivity Specificity PPV NPV Accuracy 
positive positive negative negative (%) (%) (%) (%) (%)
Atrophic 11 2 13 0 100 86.7 84.6 100 92.3
gastritis* (n = 26)
Non-atrophic 82 3 34 3 96.5 91.9 96.5 91.9 95.1
gastritis (n = 122)
*Atrophic gastritis was defined as serum pepsinogen-I ≤ 70 ng/mL and pepsinogen-I/pepsinogen-II ratio ≤ 3. PPV = positive predictive value; NPV = negative pre-
dictive value; ELISA = HEL-pTEST II (quantitative ELISA test).
lymphoid tissue) lymphoma].18,24,26 In serology assays,
prior use of antibiotics, anti-secretory treatment, loca-
tion, and reduced number of H. pylori in the gastric mu-
cosa have no effect on diagnostic accuracy.12 In contrast,
anti-secretory treatments before gastroscopy may lead
to false-negative results for histology, culture, and ure-
ase tests.27,28 Although histology, culture, and even the
urea breath test remain negative, patients with atro-
phic corpus gastritis often have positive serology re-
sults.11,24,29,30 Such patients may still be infected because
antibody titers rapidly fall after eradication therapy.31
The sensitivity of both the urea breath test and
histology are low in atrophic gastritis.24 Low bacterial
density results in a decreased H. pylori detection rate by
the gold standard and increases the false-negative rate
of the gold standard. When the gold standard is used
for H. pylori detection in patients with a low bacterial
load, the false-positive rate of serology increases, with
concomitant decreased specificity. The exclusion of
patients with atrophic gastritis improves the specificity
for those with an older age.11 In the present study,
ELISA showed a higher specificity in the non-atrophic
group compared with the atrophic group. Taken to-
gether, these findings indicated that the lower specificity
in the older age group was due to the false-negative
of the gold standard rather than the false-positive of
serology.
In conclusion, serology is a good noninvasive test,
even in older age groups, and is a suitable test in patients
with gastric ulcer, gastric cancer, or pernicious anemia
in which atrophic gastritis is more prevalent.5,32–34
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